High pathologic complete response in her-2-positive locally advanced breast cancer(LABC) after primary systemic chemotherapy with weekly docetaxel and epirubicin

被引：0
|
作者：
Chen, Shin-Cheh
Lin, Yung-Chang
Chang, Hsien-Kun
Hsueh, Swei
Leung, Wai-Man
Tsai, Chien-Sheng
Lo, Yung-Feng
Tsai, Hsiu-Pei
Shen, Shih-Che
Chen, Miin-Fu
机构：
[1] Chang Gung Mem Hosp, Dept Surg, Taipei 10591, Taiwan
[2] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan
[3] Chang Gung Mem Hosp, Dept Diagnost Radiol, Taipei 10591, Taiwan
[4] Chang Gung Mem Hosp, Dept Radiat Oncol, Taipei 10591, Taiwan
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [21] Gene expression profiles can predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast cancer
    不详
    [J]. BREAST, 2005, 14 : S21 - S21
  • [22] Complete pathologic response after neoadjuvant chemotherapy in locally advanced colon cancer
    Arredondo, Jorge
    Simo, Vicente
    Castanon, Carmen
    Jose Suarez, Maria
    Concepcion Alvarez, Maria
    [J]. CIRUGIA ESPANOLA, 2020, 98 (03): : 168 - 170
  • [23] Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast
    Schneeweiss, A
    Thuerigen, O
    Toedt, G
    Warnat, P
    Hahn, M
    Rudlowski, C
    Benner, A
    Brors, B
    Sohn, C
    Lichter, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 135S - 135S
  • [24] Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
    Heidy Cedeño
    Rafael Araúz
    Fernando Cebamanos
    Idalmis de Torraza
    Ana Porcell
    [J]. BMC Cancer, 7 (Suppl 1)
  • [25] Histologic findings after primary chemotherapy in locally-advanced breast cancer (LABC) patients
    Visca, P.
    Perracchio, L.
    Conti, F.
    Sergi, D.
    Scibilia, C.
    Lopez, M.
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 143 - 143
  • [26] Can MRI Predict Pathologic Complete Response After Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer?
    Lee, C.
    Le-Tran, V.
    Olimpiadi, Y.
    Zaremba, N.
    Nelson, M.
    Lang, J. E.
    Sener, S. F.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S90 - S90
  • [27] Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer
    Thuerigen, O
    Schneeweiss, A
    Toedt, G
    Warnat, P
    Hahn, M
    Kramer, H
    Brors, B
    Rudlowski, C
    Benner, A
    Schuetz, F
    Tews, B
    Eils, R
    Sinn, HP
    Sohn, C
    Lichter, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1839 - 1845
  • [28] High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study.
    Milla, A
    Morales, S
    Burillo, MA
    Borrega, P
    Machenes, I
    Checa, T
    Janariz, J
    Illaramendi, JJ
    Lizon, J
    Gonzalez-Baron, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 271 - 271
  • [29] Pathological Complete Response (PCR) with TDM1 (Trastuzumab Emtansine) in Refractory HER2-Positive Locally Advanced Breast Cancer (LABC)
    Dhanushkodi, Manikandan
    Iyer, Priya
    Ananthi, Balasubramanian
    Krishnamurthy, Arvind
    [J]. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (01)
  • [30] A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
    Trudeau, Maureen Elizabeth
    Chapman, Judith-Anne W.
    Guo, Baoqing
    Clemons, Mark J.
    Dent, Rebecca A.
    Jong, Roberta A.
    Kahn, Harriette J.
    Pritchard, Kathleen I.
    Han, Lei
    O'Brien, Patti
    Shepherd, Lois E.
    Parissenti, Amadeo M.
    [J]. SPRINGERPLUS, 2015, 4
12345